Treatment-focused DNA testing for newly diagnosed breast cancer patients: Some implications for clinical practice

Clinical Genetics

Volumn 77, Issue 4, 2010, Pages 350-354

  Lobb, E A ^a,b   Barlow Stewart, K ^c   Suthers, G ^d   Hallowell, N ^e  

^a Calvary Health Care Sydney   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c New South Wales Government   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

BRCA1 and BRCA2; Breast cancer; DNA testing; Newly diagnosed women

Indexed keywords

ARTICLE; AUSTRALIA; BREAST CANCER; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FAMILIAL CANCER; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; INFORMED CONSENT; PRIORITY JOURNAL;

AUSTRALIA; BREAST NEOPLASMS; DECISION MAKING; DNA, NEOPLASM; FAMILY; FEMALE; GENETIC TESTING; HUMANS; INFORMED CONSENT; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77951728310     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01307.x     Document Type: Article

References (15)

1. American society of clinical oncology policy statement. J Clin Oncol 2003, 21:2397-2406. American Society of Clinical Oncology
2. Guidelines on familial aspects of cancer 1999, Australian Cancer Network, Sydney, Australian Cancer Network
3. Mitchell G, Arden-Jones A, Kissin-Mchir M. A paradox: urgent BRCA genetic testing. Fam Cancer 2001, 1:25-29.
4. Farmer H, McCabe N, Lord C. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-920.
5. Hartmann L, Sellers T, Schaid D. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93(21):1633-1637.
6. Weitzel JN, McCaffery SM, Nedelcu R. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003, 138:1323-1328.
7. Metcalfe K, Lynch HT, Ghadirian P. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin Oncol 2004, 22:2328-2353.
8. Pierce LJ, Levin AM, Rebbeck TR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/BRCA2 associated stage I/II Breast cancer. J Clin Oncol 2006, 24:2437-2443.
9. Quinn JE, James CR, Stewart GE. BRCA1 mRNA expression levels predict overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13:7414-7420.
10. Rottenburg S, Nygren AO, Pajic M. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007, 104:12117-12122.
11. De Soto J, Deng C. PARP-inhibitors: are they the long-sought genetically specific drugs for BRCA1/BRCA2 associated breast cancers? Int J Med Sci 2006, 3:117-123.
12. Farmer H, McCabe N, Lord C. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-920.
13. Meiser B, Tucker K, Friedlander M. Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res Treat 2008, 10:216-230.
14. Ardern-Jones A, Kenen R, Eeles R. Too much too soon? Patients' and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care 2005, 14:272-281.
15. Strauss A, Corbin J. Basics of qualitative research 1990, London, Sage